200 related articles for article (PubMed ID: 38103163)
1. Endocrinopathies in beta thalassemia: a narrative review.
Venou TM; Barmpageorgopoulou F; Peppa M; Vlachaki E
Hormones (Athens); 2023 Dec; ():. PubMed ID: 38103163
[TBL] [Abstract][Full Text] [Related]
2. Endocrinopathies, metabolic disorders, and iron overload in major and intermedia thalassemia: serum ferritin as diagnostic and predictive marker associated with liver and cardiac T2* MRI assessment.
Chirico V; Rigoli L; Lacquaniti A; Salpietro V; Piraino B; Amorini M; Salpietro C; Arrigo T
Eur J Haematol; 2015 May; 94(5):404-12. PubMed ID: 25200112
[TBL] [Abstract][Full Text] [Related]
3. Severe Liver Iron Concentrations (LIC) in 24 Patients with β-Thalassemia Major: Correlations with Serum Ferritin, Liver Enzymes and Endocrine Complications.
Kanbour I; Chandra P; Soliman A; De Sanctis V; Nashwan A; Abusamaan S; Moustafa A; Yassin MA
Mediterr J Hematol Infect Dis; 2018; 10(1):e2018062. PubMed ID: 30416694
[TBL] [Abstract][Full Text] [Related]
4. Endocrinopathies in Hemoglobinopathies: What Is the Role of Iron?
Evangelidis P; Venou TM; Fani B; Vlachaki E; Gavriilaki E;
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003451
[TBL] [Abstract][Full Text] [Related]
5. Beta-Thalassemia Intermedia: A Single Thalassemia Center Experience from Northeastern Iraq.
Amin SS; Jalal SD; Ali KM; Mohammed AI; Rasool LK; Osman TJ
Biomed Res Int; 2020; 2020():2807120. PubMed ID: 32190657
[TBL] [Abstract][Full Text] [Related]
6. Serum ferritin levels and endocrinopathy in medically treated patients with β thalassemia major.
Belhoul KM; Bakir ML; Saned MS; Kadhim AM; Musallam KM; Taher AT
Ann Hematol; 2012 Jul; 91(7):1107-14. PubMed ID: 22281991
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of endocrine complications in transfusion dependent thalassemia in Hospital Pulau Pinang: A pilot study.
Lee KT; Lim SL; Goh AS
Med J Malaysia; 2020 Jan; 75(1):33-37. PubMed ID: 32008017
[TBL] [Abstract][Full Text] [Related]
8. New Entity-Thalassemic Endocrine Disease: Major Beta-Thalassemia and Endocrine Involvement.
Carsote M; Vasiliu C; Trandafir AI; Albu SE; Dumitrascu MC; Popa A; Mehedintu C; Petca RC; Petca A; Sandru F
Diagnostics (Basel); 2022 Aug; 12(8):. PubMed ID: 36010271
[TBL] [Abstract][Full Text] [Related]
9. Clinical utility of endocrine markers predicting myocardial siderosis in transfusion dependent thalassemia major.
Ehsan L; Rashid M; Alvi N; Awais K; Nadeem O; Asghar A; Sajjad F; Fatima M; Qidwai A; Hussain S; Hasan E; Brown N; Altaf S; Hasan B; Kirmani S
Pediatr Blood Cancer; 2018 Oct; 65(10):e27285. PubMed ID: 29893484
[TBL] [Abstract][Full Text] [Related]
10. Impact of genotype on endocrinal complications in β-thalassemia patients.
Al-Akhras A; Badr M; El-Safy U; Kohne E; Hassan T; Abdelrahman H; Mourad M; Brintrup J; Zakaria M
Biomed Rep; 2016 Jun; 4(6):728-736. PubMed ID: 27284414
[TBL] [Abstract][Full Text] [Related]
11. The impact of genotype on endocrine complications in thalassaemia major.
Skordis N; Michaelidou M; Savva SC; Ioannou Y; Rousounides A; Kleanthous M; Skordos G; Christou S
Eur J Haematol; 2006 Aug; 77(2):150-6. PubMed ID: 16800840
[TBL] [Abstract][Full Text] [Related]
12. Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre.
Gamberini MR; De Sanctis V; Gilli G
Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():158-69. PubMed ID: 19337172
[TBL] [Abstract][Full Text] [Related]
13. Beta-thalassemia.
Galanello R; Origa R
Orphanet J Rare Dis; 2010 May; 5():11. PubMed ID: 20492708
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of endocrine disorders and their associated factors in transfusion-dependent thalassemia patients: a historical cohort study in Southern Iran.
Bordbar M; Bozorgi H; Saki F; Haghpanah S; Karimi M; Bazrafshan A; Zekavat OR
J Endocrinol Invest; 2019 Dec; 42(12):1467-1476. PubMed ID: 31228105
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years.
Poggi M; Sorrentino F; Pugliese P; Smacchia MP; Daniele C; Equitani F; Terlizzi F; Guitarrini MR; Monti S; Maffei L; Losardo A; Pasin M; Toscano V
Ann Hematol; 2016 Apr; 95(5):757-63. PubMed ID: 26957357
[TBL] [Abstract][Full Text] [Related]
16. Current status of beta-thalassemia and its treatment strategies.
Ali S; Mumtaz S; Shakir HA; Khan M; Tahir HM; Mumtaz S; Mughal TA; Hassan A; Kazmi SAR; Sadia ; Irfan M; Khan MA
Mol Genet Genomic Med; 2021 Dec; 9(12):e1788. PubMed ID: 34738740
[TBL] [Abstract][Full Text] [Related]
17. Final Height and Endocrine Complications in Patients with β-Thalassemia Intermedia: Our Experience in Non-Transfused Versus Infrequently Transfused Patients and Correlations with Liver Iron Content.
Yassin MA; Soliman AT; De Sanctis V; Yassin KS; Abdulla MA
Mediterr J Hematol Infect Dis; 2019; 11(1):e2019026. PubMed ID: 31205630
[TBL] [Abstract][Full Text] [Related]
18. Hypoparathyroidism in transfusion-dependent patients with beta-thalassemia.
Chern JP; Lin KH
J Pediatr Hematol Oncol; 2002 May; 24(4):291-3. PubMed ID: 11972098
[TBL] [Abstract][Full Text] [Related]
19. Thalassemia.
Cohen AR; Galanello R; Pennell DJ; Cunningham MJ; Vichinsky E
Hematology Am Soc Hematol Educ Program; 2004; ():14-34. PubMed ID: 15561674
[TBL] [Abstract][Full Text] [Related]
20. History of myocardial iron loading is a strong risk factor for diabetes mellitus and hypogonadism in adults with β thalassemia major.
Ang AL; Tzoulis P; Prescott E; Davis BA; Barnard M; Shah FT
Eur J Haematol; 2014 Mar; 92(3):229-36. PubMed ID: 24164584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
